ROGAINE (FOR MEN)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROGAINE (FOR MEN) (ROGAINE (FOR MEN)).
Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation and increased cutaneous blood flow. It also stimulates hair follicles by prolonging the anagen phase and increasing follicular size via activation of prostaglandin synthesis and upregulation of vascular endothelial growth factor (VEGF).
| Metabolism | Minoxidil is primarily metabolized in the liver by glucuronidation via UGT1A1 and UGT1A9 enzymes, as well as sulfation. A minor pathway involves N-oxidation. The major metabolite is minoxidil glucuronide, which is excreted renally. |
| Excretion | Approximately 60% of absorbed minoxidil is metabolized, primarily by conjugation with glucuronic acid. The remaining 40% is excreted unchanged in urine. Renal excretion is the major route, with unchanged drug and metabolites eliminated via the kidneys. Fecal excretion accounts for <3%. |
| Half-life | Terminal elimination half-life is approximately 4.2 hours (range 2.5–5.5 hours) in patients with normal renal function. However, the pharmacodynamic half-life (duration of antihypertensive effect) is longer, correlating with its prolonged tissue binding. |
| Protein binding | Approximately 20% bound to plasma proteins (albumin). |
| Volume of Distribution | Approximately 2.5–3.2 L/kg, indicating extensive distribution into tissues, including vascular smooth muscle (site of action) and hair follicles. |
| Bioavailability | Oral: Approximately 90% absorbed, but first-pass metabolism reduces systemic bioavailability to about 50% (range 30–70%). Topical: Systemic absorption is minimal (1.4% of applied dose) and does not produce clinically significant cardiovascular effects. |
| Onset of Action | Topical solution: Hypotensive effect (oral) begins within 30 minutes; for hair regrowth, visible results typically require 4–6 months of twice-daily application. Oral: Antihypertensive effect begins within 30 minutes, with peak effect at 2–3 hours. |
| Duration of Action | Oral: Antihypertensive effect lasts approximately 24 hours with twice-daily dosing. Topical: Once hair regrowth occurs, continued application is required to maintain effect; discontinuation leads to reversal within 3–6 months. |
1 mL of 5% solution applied topically to the scalp twice daily (total daily dose 2 mL).
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment; minimal systemic absorption. |
| Liver impairment | No dose adjustment required for hepatic impairment; minimal systemic absorption. |
| Pediatric use | Not indicated for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; apply 1 mL twice daily as in adults, monitor for local irritation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ROGAINE (FOR MEN) (ROGAINE (FOR MEN)).
| Breastfeeding | Minoxidil is excreted in human milk. M/P ratio unknown. Potential for severe adverse effects in nursing infants (e.g., hypotension, electrolyte disturbances). Breastfeeding not recommended during treatment. |
| Teratogenic Risk | Minoxidil (Rogaine for Men) is Pregnancy Category C. First trimester: No adequate human studies, animal studies show fetal abnormalities at high doses. Second and third trimesters: Risk cannot be ruled out; avoid use due to potential for fetal harm including skeletal and cardiac defects. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to minoxidil or any component of the formulation.","Use on broken, irritated, or sunburned scalp.","Concomitant use of other topical or systemic vasodilators without medical supervision.","Severe underlying cardiovascular disease (e.g., unstable angina, recent myocardial infarction)."]
| Precautions | ["Cardiovascular risks: May cause reflex tachycardia, fluid retention, and pericardial effusion, especially with systemic absorption.","Dermatological reactions: Local irritation, dermatitis, and rarely hypertrichosis on face or other body areas.","Ophthalmic effects: Blurred vision or eye irritation if accidentally sprayed into eyes.","Hypotension: Potential for orthostatic hypotension with excessive use.","Monitoring: Blood pressure and heart rate should be monitored in patients with known cardiovascular disease."] |
Loading safety data…
| Fetal Monitoring |
| If inadvertent exposure occurs, no specific monitoring required for topical use due to low systemic absorption. For oral minoxidil (off-label in pregnancy), monitor maternal blood pressure, heart rate, and fetal growth/well-being via ultrasound. |
| Fertility Effects | No known adverse effects on human fertility from topical minoxidil. Animal studies show no impairment of fertility at clinically relevant doses. |